Monday broker round-up
22nd Oct 2018 12:35
(Sharecast News) - British Land: Credit Suisse downgrades to underperform with a target price of 620p.
Read moreAstraZeneca gets positive opinion for COPD treatment
19th Oct 2018 07:50
(Sharecast News) - AstraZeneca received a thumbs-up from European regulators about its metered-dose inhaler to treat chronic obstructive pulmonary disease.
Read moreAstraZeneca and Merck get designation for Lynparza in pancreatic cancer
16th Oct 2018 08:03
(Sharecast News) - AstraZeneca, alongside Merck & Co, announced on Tuesday that the two parties have been granted orphan drug designation (ODD) by the US Food and Drug Administration for Lynparza (olaparib) for the treatment of pancreatic cancer.
Read moreMonday broker round-up
8th Oct 2018 13:07
(Sharecast News) - Mediclinic International: Investec upgrades to buy with a target price of 448p.
Read moreAstraZeneca drug cuts lung cancer deaths by nearly a third
25th Sep 2018 16:25
(Sharecast News) - A clinical study has shown AstraZeneca's immunotherapy drug Imfinzi to have reduced the risk of death in patients with mid-stage lung cancer by nearly a third in a clinical study.
Read moreTuesday broker round-up
25th Sep 2018 12:57
(Sharecast News) - Wetherspoons: Peel Hunt downgrades to hold with a target price of 1,325p.
Read moreMonday broker round-up
24th Sep 2018 12:59
(Sharecast News) - Thomas Cook: Shore Capital Markets downgrades to hold.
Read moreAstraZeneca reveals positive results from Farxiga cardiovascular trial
24th Sep 2018 07:21
(Sharecast News) - AstraZeneca announced positive results from the phase III DECLARE-TIMI 58 cardiovascular outcomes trial for 'Farxiga' dapagliflozin, which it said was the broadest SGLT2 inhibitor cardiovascular outcome trial conducted to date.
Read moreAstraZeneca's Lumoxiti gets FDA approval as hairy cell leukaemia treatment
14th Sep 2018 07:20
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced on Friday that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia.
Read moreMonday broker round-up
10th Sep 2018 11:48
(Sharecast News) - Glencore: JP Morgan downgrades to neutral with a target price of 370p.
Read moreAstraZeneca gets 'breakthrough' designation for tezepelumab asthma treatment
7th Sep 2018 07:31
(Sharecast News) - AstraZeneca and its partner Amgen announced on Friday that the US Food and Drug Administration (FDA) has granted 'Breakthrough Therapy Designation' for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids or long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Read moreAstraZeneca's anifrolumab trial fails to meet primary endpoint
31st Aug 2018 09:00
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE) on Friday.
Read moreAstraZeneca gets EC approval for Bydureon BCise
30th Aug 2018 07:23
(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a new formulation within the marketing authorisation for Bydureon for the treatment of patients with type-2 diabetes.
Read moreAstraZeneca analysing 'inconsistent' results from Bevespi Aerosphere trial
23rd Aug 2018 07:23
(Sharecast News) - AstraZeneca announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) on Thursday.
Read moreAstraZeneca gets further approval for Tagrisso in Japan
21st Aug 2018 07:23
(Sharecast News) - AstraZeneca announced on Tuesday that the Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib) for the first-line treatment of patients with inoperable or recurrent epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), following priority review.
Read more